Linked research, clinical, and regulatory source pathways.
Company profile
About Indica Labs
Indica Labs is the global leader in AI-powered digital pathology, redefining medicine with comprehensive pathology platforms that support the entire translational journey from basic science research to clinical diagnostics. The company's flagship HALO software suite integrates image management and quantitative image analysis to deliver standardized, reproducible tissue-based analysis at every stage of drug development and patient care. Founded to advance pathology through artificial intelligence, Indica Labs serves research institutions, pharmaceutical companies, clinical laboratories, and diagnostic centers worldwide. The company's solutions span from HALO AI for trainable AI in research settings to HALO AP Dx, an FDA-cleared case-centric pathology platform enabling primary diagnosis and remote working in anatomic pathology. Their clinical AI portfolio includes CE-IVD marked tools for prostate cancer detection and Gleason grading, breast IHC biomarker quantification (HER2, ER, PR, Ki67), lung PD-L1 expression analysis, and slide quality control. Indica Labs has achieved deployments across all top 20 pharmaceutical companies and maintains a global presence with employees in 12 countries. The company's technology has been utilized in thousands of peer-reviewed publications and is deployed in laboratories around the world. Their comprehensive service offerings include AI-powered companion diagnostics development, pharma services, AWS-hosted cloud services, and integration and migration support. With enterprise-grade security, flexible deployment options (on-premise or cloud), and seamless integration with existing laboratory information systems, Indica Labs delivers end-to-end digital pathology workflows that improve diagnostic accuracy, efficiency, and patient care.
Company description Indica Labs official website
Primary marketPathology & Laboratory Diagnostics
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Indica Labs?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Breast cancer (HER2, ER, PR, Ki67)
- Colorectal carcinoma
- General anatomic pathology
- Non-small cell lung cancer (NSCLC)
- Prostate adenocarcinoma
Who it serves
- Academic medical centers
- Clinical laboratories
- Diagnostic pathology labs
- Government research institutes
- NHS trusts
- Pharmaceutical companies
- Research institutions
Deployment & integration
Deployment information is currently being developed.
Recorded integration context: Aperio eSlideManager, Aperio GT 450 DX Scanner, Hamamatsu NanoZoomer, Leica Biosystems scanners, LIMS, LIS (Laboratory Information Systems).
Geographic context
MarketsChina · European Union · Global · Japan · Switzerland · United Kingdom · United States
Company sourceOfficial website
Company milestones
Platform expansion
FDA clearance for HALO AP Dx, CE-IVDR marking for HALO AP, deployment across all top 20 pharma companies, Best in KLAS award, AI-powered companion diagnostics offering unveiled ahead of ASCO
Partnerships
Recorded partners
- AWS (Amazon Web Services)
- Barco
- Dell
- Hamamatsu
- Leica Biosystems
- Lunit
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
No source-backed Company products are currently listed.
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
A spatial immune scoring system based on the tumor microenvironment features improves prognostic stratification in lung adenocarcinoma.Translational oncology · Jun 19, 2026
AI-driven spatial mapping of myxoid stroma and tumor-infiltrating lymphocytes in esophageal squamous cell carcinoma.Esophagus : official journal of the Japan Esophageal Society · Jan 1, 2026
Society for Immunotherapy of Cancer: Standards for Reporting of Multiplex Immunohistochemistry/Immunofluorescence Assays (STORMI).Journal for immunotherapy of cancer · Dec 21, 2025
Small things matter: Lack of extraislet β cells in type 1 diabetes.Science advances · Nov 14, 2025
Increased Expression of Secreted Form A Disintegrin and Metalloproteinase 28 (ADAM28s) in Esophageal Squamous Cell Carcinoma: Implication for Carcinoma Cell Proliferation via Interleukin 6 Receptor Shedding.Laboratory investigation; a journal of technical methods and pathology · Nov 1, 2025
Quantitative temporal analysis of pancreatic islet T lymphocyte and macrophage infiltration heralded by serum IgE in congenic BioBreeding (BB) Gimap5-/- rats at risk for insulitis and acute onset diabetes.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · Oct 3, 2025
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Faster diagnoses
Remote case review immediately after scanning
Standardized scoring
AI-based decision support for Gleason grading and biomarker quantification
Improved accuracy and reproducibility
Standardized tissue-based analysis across workflows
Decreased monthly costs
Cloud deployment vs on-premise infrastructure
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Indica Labs
Recent articles published on Indica Labs's official website.
Lab Logic Brings Intelligent Case Orchestration to HALO AP® and HALO AP Dx
Read on Indica LabsWorkshop: HALOを用いたMASHモデルマウスの定量的病理組織解析とその有用性
Read on Indica LabsAutomating Tissue Macro-Dissection with Insight
Read on Indica LabsSneak Peek Into the New Features of HALO®, HALO AI, and HALO Link 4.4
Read on Indica LabsWhat is new in HALO®, HALO AI, and HALO Link 4.3?
Read on Indica Labs07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Pathology & Laboratory Diagnostics
Companies applying AI to digital pathology, histopathology slide analysis, laboratory diagnostics, or biomarker discovery. Includes AI-powered interpretation of lab test results, at-home diagnostic devices with AI analysis, and platforms that analyze tissue samples or biological specimens to support clinical diagnosis.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.